Understanding the neural mechanisms of lisdexamfetamine dimesylate (LDX) pharmacotherapy in Binge‐Eating Disorder
Binge Eating Disorder (BED) is the most common eating disorder in Australia. It can occur in people of all ages and genders, socioeconomic groups and cultural backgrounds. LDX is currently the only medication which is indicated for BED by the Therapeutic Goods Administration. Despite this, the exact mode of its therapeutic action and its neural mechanisms remain largely unknown.
Participate in our research
Do you binge-eat at least 3 days a week? Are you distressed about your binge eating?
You may* be eligible to participate in a clinical trial looking at how the medication LDX works to reduce binge-eating symptoms if:
* You are 18 - 40 years old
* You have Moderate to Severe Binge-Eating Disorder as assessed by a clinician at Westmead Hospital
* Your Body Mass Index is 20 - 45kg/m2
This study is sponsored by the University of Sydney and has been approved by the WSLHD Human Research Ethics Committee.
If you are interested in participating, contact Jenny on 8627 3321 or email@example.com
*Please note that certain exclusion criteria may prevent you from participating in the study.